Pfizer Inc. (NYSE:PFE) – Research analysts at Jefferies Group cut their FY2017 earnings per share (EPS) estimates for Pfizer in a report released on Thursday. Jefferies Group analyst J. Holford now expects that the firm will post earnings of $2.67 per share for the year, down from their prior estimate of $2.71. Jefferies Group has a “Hold” rating and a $36.00 price objective on the stock. Jefferies Group also issued estimates for Pfizer’s FY2018 earnings at $2.92 EPS, FY2019 earnings at $2.87 EPS and FY2020 earnings at $3.08 EPS.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. The firm earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.56 earnings per share.

Earnings History and Estimates for Pfizer (NYSE:PFE)

Several other equities research analysts have also commented on PFE. Argus restated a “buy” rating and set a $39.00 price target on shares of Pfizer in a research note on Sunday, August 28th. Vetr upgraded Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.94 price target for the company in a research note on Monday, June 27th. Barclays PLC restated an “equal weight” rating and set a $34.00 price target on shares of Pfizer in a research note on Tuesday, August 2nd. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, July 20th. Finally, Sanford C. Bernstein set a $36.00 price target on Pfizer and gave the stock a “buy” rating in a research note on Wednesday. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Pfizer has a consensus rating of “Buy” and an average price target of $38.55.

Pfizer (NYSE:PFE) traded down 0.43% during midday trading on Monday, reaching $32.55. The company had a trading volume of 4,429,111 shares. Pfizer has a 12 month low of $28.25 and a 12 month high of $37.39. The firm has a market capitalization of $197.44 billion, a PE ratio of 28.86 and a beta of 0.86. The firm’s 50-day moving average price is $33.89 and its 200 day moving average price is $34.37.

Several hedge funds have recently made changes to their positions in PFE. Ronna Sue Cohen increased its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares during the period. Forte Capital LLC ADV increased its stake in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock valued at $255,000 after buying an additional 36 shares during the period. Delphi Private Advisors LLC increased its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares during the period. Acadia Trust NA increased its stake in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 67 shares during the period. Finally, New England Private Wealth Advisors LLC increased its stake in shares of Pfizer by 0.4% in the second quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company’s stock valued at $639,000 after buying an additional 77 shares during the period. 69.66% of the stock is currently owned by institutional investors and hedge funds.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio (DPR) is 95.24%.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.